Our laboratory has been testing the hypothesis that genetic modulation of the beta-
adrenergic signaling cascade can enhance cardiac function. We have previously shown that transgenic mice with cardiac overexpression of either the human beta2-adrenergic receptor (beta2AR) or an inhibitor of the
beta-adrenergic receptor kinase (betaARK), an
enzyme that phosphorylates and uncouples agonist-bound receptors, have increased myocardial inotropy. We now have created recombinant adenoviruses encoding either the beta2AR (Adeno-beta2AR) or a
peptide betaARK inhibitor (consisting of the carboxyl terminus of betaARK1, Adeno-
betaARKct) and tested their ability to potentiate beta-
adrenergic signaling in cultured adult rabbit ventricular myocytes. As assessed by radioligand binding, Adeno-beta2AR
infection led to approximately 20-fold overexpression of
beta-adrenergic receptors.
Protein immunoblots demonstrated the presence of the Adeno-
betaARKct transgene. Both transgenes significantly increased
isoproterenol-stimulated cAMP as compared to myocytes infected with an adenovirus encoding
beta-galactosidase (Adeno-betaGal) but did not affect the sarcolemmal
adenylyl cyclase response to
Forskolin or NaF.
beta-Adrenergic agonist-induced desensitization was significantly inhibited in Adeno-
betaARKct-infected myocytes (16+/-2%) as compared to Adeno-betaGal-infected myocytes (37+/-1%, P < 0.001). We conclude that recombinant adenoviral gene transfer of the beta2AR or an inhibitor of betaARK-mediated desensitization can potentiate beta-
adrenergic signaling.